Haystack MRD
Use
Haystack MRD is a minimally invasive tumor-informed test designed to detect circulating tumor DNA (ctDNA) in blood samples to monitor treatment response and detect residual or recurrent disease. The test provides critical insights into a patient's disease status, helping to guide adjuvant chemotherapy decisions and monitor treatment response in real time. It provides an early indication of cancer recurrence, with a limit of detection at 0.0006% tumor fraction, enabling earlier intervention than traditional methods.
Special Instructions
This test is tumor-informed and personalized for each patient, tracking up to 50 variants. It is suitable for baseline and continual monitoring throughout a patient's care journey. Attention to detail in sample collection and handling is crucial to ensure accuracy and reliability of results.
Limitations
Due to its high sensitivity, the test is optimized for detecting ctDNA at very low levels, which may not be detectable by other MRD tests. However, the detection capabilities are contingent on the accurate sequencing of patient-specific variants, which requires high-quality sample collection and processing. Variations in ctDNA levels may be influenced by factors unrelated to actual tumor burden, such as physiological changes or technical variability, necessitating comprehensive clinical correlation.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided